tocilizumab,obinutuzumab,glofitamab
jw pharma,roche
['dlbcl', 'glofitamab', 'cml']
#17icml bispecific treatments produced among 19%-49% of complete responses in dlbcl, being glofitamab the highest. this is the most important opportunity for latam because platforms for cart are far away. 
Happily married. Hematologist & SC Transplanter. field of interest: lymphoma-myeloma &chemoresistance biomarkers. @HematoClinicBCN @hematosantpau.@GELL01433166